Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wellell Inc. (4106.TW)
TWD25.00
+0.15 (+0.60%)
TW TAI Healthcare Medical - Devices
Address
No. 9, Min Sheng Street 23679
New Taipei City, TW
New Taipei City, TW
CEO
Yong-Chuan Li
Website
wellell.com/en
IPO
2004-11-08
ISIN TW0004106000
Description
Established in 1990 in New Taipei City, Taiwan, Wellell Inc. is a global enterprise active in the medical supplies sector. The company's activities span research and development, manufacturing, and the international distribution (import, export, and sales) of its diverse product portfolio. This includes items for wound care, respiratory therapy devices, assistive welfare equipment, and other electronic medical instruments. Wellell's specific offerings feature pressure relief mattresses and seating, as well as advanced solutions for sleep apnea, such as auto-adjusting pressure systems and their Sleepwell product line. These innovative solutions primarily focus on the prevention of pressure injuries and the management of obstructive sleep apnea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
TWD25.00
+0.15 (+0.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
145.1K
Beta
0.35
Float Shares
71.75M
Free Float %
71.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.44% | +2.24% | +1.33% | -1.51% | +5.07% | +3.40% | -1.51% | -27.62% | -46.29% | -40.00% | +110.14% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
25.00
DCF (Unlevered)
55.03
+120.1%
DCF (Levered)
100.61
+302.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.79
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+0.7% Q1'26: +4.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+5.3% Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+4.4% Q1'26: +22.4% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+6.3% ★ Q1'26: +10.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+5.7% ★ Q1'26: +9.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.1% Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.98× ★ Q1'26: 1.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
Dec 2032 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.02B
est: 2.03B (-0.5%)
|
1.99B
est: 1.98B (+0.5%)
|
2.09B
est: 2.11B (-1.1%)
|
2.11B
est: 2.24B (-6.2%)
|
2.00B
est: 1.99B (+0.8%)
|
2.37B
est: 2.39B (-0.5%)
|
2.66B
est: 2.64B (+1.1%)
|
2.65B
est: 2.90B (-8.7%)
|
2.40B
est: 2.11B (+13.8%)
|
2.11B
2.11B – 2.11B
+0.0% YoY
|
2.24B
2.24B – 2.24B
+6.2% YoY
|
1.99B
1.99B – 1.99B
-11.4% YoY
|
1.99B
1.99B – 1.99B
+0.0% YoY
|
2.39B
2.39B – 2.39B
+20.0% YoY
|
2.64B
2.64B – 2.64B
+10.4% YoY
|
2.90B
2.90B – 2.90B
+10.1% YoY
|
| EBITDA |
330.65M
est: 222.03M (+48.9%)
|
272.54M
est: 217.06M (+25.6%)
|
250.94M
est: 231.64M (+8.3%)
|
226.14M
est: 246.00M (-8.1%)
|
211.28M
est: 217.93M (-3.1%)
|
238.98M
est: 261.56M (-8.6%)
|
305.21M
est: 288.86M (+5.7%)
|
318.12M
est: 317.91M (+0.1%)
|
254.61M
est: 227.01M (+12.2%)
|
227.01M
227.01M – 227.01M
+0.0% YoY
|
241.09M
241.09M – 241.09M
+6.2% YoY
|
213.58M
213.58M – 213.58M
-11.4% YoY
|
213.58M
213.58M – 213.58M
+0.0% YoY
|
256.34M
256.34M – 256.34M
+20.0% YoY
|
283.10M
283.10M – 283.10M
+10.4% YoY
|
311.57M
311.57M – 311.57M
+10.1% YoY
|
| EBIT |
209.75M
est: 145.35M (+44.3%)
|
159.30M
est: 142.09M (+12.1%)
|
161.12M
est: 151.64M (+6.3%)
|
159.96M
est: 161.04M (-0.7%)
|
134.12M
est: 142.67M (-6.0%)
|
145.75M
est: 171.23M (-14.9%)
|
210.72M
est: 189.10M (+11.4%)
|
224.04M
est: 208.12M (+7.7%)
|
150.83M
est: 150.31M (+0.3%)
|
150.31M
150.31M – 150.31M
+0.0% YoY
|
159.63M
159.63M – 159.63M
+6.2% YoY
|
141.42M
141.42M – 141.42M
-11.4% YoY
|
141.42M
141.42M – 141.42M
+0.0% YoY
|
169.73M
169.73M – 169.73M
+20.0% YoY
|
187.44M
187.44M – 187.44M
+10.4% YoY
|
206.30M
206.30M – 206.30M
+10.1% YoY
|
| Net Income |
168.75M
est: 203.21M (-17.0%)
|
122.50M
est: 177.51M (-31.0%)
|
118.26M
est: 199.83M (-40.8%)
|
108.41M
est: 170.41M (-36.4%)
|
104.59M
est: 102.45M (+2.1%)
|
102.25M
est: 125.78M (-18.7%)
|
161.40M
est: 172.44M (-6.4%)
|
152.17M
est: 179.54M (-15.2%)
|
121.12M
est: 199.98M (-39.4%)
|
199.98M
199.98M – 199.98M
+0.0% YoY
|
170.54M
170.54M – 170.54M
-14.7% YoY
|
102.53M
102.53M – 102.53M
-39.9% YoY
|
102.53M
102.53M – 102.53M
+0.0% YoY
|
125.88M
125.88M – 125.88M
+22.8% YoY
|
172.57M
172.57M – 172.57M
+37.1% YoY
|
179.68M
179.68M – 179.68M
+4.1% YoY
|
| SGA |
596.91M
est: 602.17M (-0.9%)
|
615.95M
est: 588.69M (+4.6%)
|
616.01M
est: 628.23M (-1.9%)
|
607.87M
est: 667.18M (-8.9%)
|
582.99M
est: 591.07M (-1.4%)
|
732.20M
est: 709.40M (+3.2%)
|
726.38M
est: 783.43M (-7.3%)
|
778.50M
est: 862.22M (-9.7%)
|
790.84M
est: 644.30M (+22.7%)
|
644.30M
644.30M – 644.30M
+0.0% YoY
|
684.24M
684.24M – 684.24M
+6.2% YoY
|
606.18M
606.18M – 606.18M
-11.4% YoY
|
606.18M
606.18M – 606.18M
+0.0% YoY
|
727.54M
727.54M – 727.54M
+20.0% YoY
|
803.47M
803.47M – 803.47M
+10.4% YoY
|
884.27M
884.27M – 884.27M
+10.1% YoY
|
| EPS |
2.02
est: 2.00 (+0.8%)
|
1.47
est: 1.75 (-16.0%)
|
1.42
est: 1.97 (-27.9%)
|
1.17
est: 1.68 (-30.4%)
|
1.04
est: 1.01 (+3.0%)
|
1.01
est: 1.24 (-18.5%)
|
1.60
est: 1.70 (-5.9%)
|
1.51
est: 1.77 (-14.7%)
|
1.20
est: 1.97 (-39.1%)
|
1.97
1.97 – 1.97
+0.0% YoY
|
1.68
1.68 – 1.68
-14.7% YoY
|
1.01
1.01 – 1.01
-39.9% YoY
|
1.01
1.01 – 1.01
+0.0% YoY
|
1.24
1.24 – 1.24
+22.8% YoY
|
1.70
1.70 – 1.70
+37.1% YoY
|
1.77
1.77 – 1.77
+4.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
103.73M
OE per share TTM
1.01
Owner's Yield
4.63%
Maintenance CapEx ratio
12.73%
Maint CapEx / Avg PPE
33.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 28.8K | 0.28% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 10.4K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
281.9K
Shares Outstanding
100.91M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alan Chang | Chief of Research & Development | — | — |
| Chang-Chi Liu | Vice President & Director | — | male |
| Pi Kai Lee | Chief Strategy Officer | — | — |
| Shin-Ho Chen | SD of Finance & Accounting Division, Corporate Governance Officer and Accounting Supervisor | — | — |
| Yong-Chuan Li | Founder, Chief Executive Officer & Chairman | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4106.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
